Studies have shown that mTOR, a classical downstream effector of the PI3K oncogenic pathway, has activity ranging from 40-90% in various solid tumors.217 Therefore, the use of mTOR as a target for cancer treatment has become a research hotspot. This evidence concerns the gene PIK3CD and cancer.